title: Peripheral administration of NR2 antagonists attenuates orofacial formalin-induced nociceptive behavior in rats.
abstract: The present study investigated the role of the peripheral NR2 subunits of N-methyl-d-aspartatic acid (NMDA) receptors in inflammatory orofacial pain. Experiments were carried out using adult male Sprague-Dawley rats weighing 220 to 280 g. Formalin (5%, 50 μl) was applied subcutaneously to the vibrissa pad. For each animal, the number of noxious behavioral responses, including rubbing or scratching of the facial region proximal to the injection site, was recorded for 9 sequential 5 min intervals. NR2 subunit antagonists were injected subcutaneously at 20 min prior to formalin injection. The subcutaneous injection of 100 or 200 μg of memantine significantly suppressed the number of scratches in the second phase of the behavioral responses to formalin. The subcutaneous injection of 0.25, 2.5, or 25 μg of 5,7-dichlorokynurenic acid also produced significant antinociceptive effects in the second phase. The subcutaneous injection of AP-5 at high dose produced significant antinociceptive effects in the second phase. The subcutaneous injection of PPPA and Ro 25-6981 both significantly suppressed the number of scratches in the second phase. The antinociceptive doses of memantine (200 μg), 5,7-dichlorokynurenic acid (25 μg), AP-5 (20 μg), PPPA (2.5 μg), or Ro 25-6981 (50 μg) injected into the contralateral hind paw did not affect the number of scratches in both the first and second phases. Moreover, the peripheral administration of NR2 subunit antagonists, including other NMDA receptor blockers, did not produce any motor dysfunction. These results indicate that a targeted blockade of peripheral NR2 receptors is a potentially important new method of treating inflammatory pain in the orofacial area.
authors.affiliation: Department of Oral Physiology, School of Dentistry, Kyungpook National University, Daegu, Republic of Korea.
authors.forename: Min K
authors.initials: MK
authors.lastname: Park
authors.forename: Ju H
authors.initials: JH
authors.lastname: Lee
authors.forename: Gwi Y
authors.initials: GY
authors.lastname: Yang
authors.forename: Kyoung A
authors.initials: KA
authors.lastname: Won
authors.forename: Min J
authors.initials: MJ
authors.lastname: Kim
authors.forename: Yoon Y
authors.initials: YY
authors.lastname: Park
authors.forename: Yong C
authors.initials: YC
authors.lastname: Bae
authors.forename: Dong K
authors.initials: DK
authors.lastname: Ahn
mesh_terms: D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects*; D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology*; D005157:Facial Pain / Q000188:drug therapy* / Q000523:psychology*; D007267:Injections; D007736:Kynurenic Acid / Q000031:analogs & derivatives / Q000494:pharmacology; D008297:Male; D008559:Memantine / Q000494:pharmacology; D010147:Pain Measurement / Q000187:drug effects*; D010636:Phenols / Q000494:pharmacology; D010880:Piperidines / Q000494:pharmacology; D004856:Postural Balance / Q000187:drug effects; D051381:Rats; D017207:Rats, Sprague-Dawley; D018009:Receptors, Glycine / Q000037:antagonists & inhibitors; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors*; D014738:Vibrissae
chemical_list: D018691:Excitatory Amino Acid Antagonists; C120997:NR2A NMDA receptor; D010636:Phenols; D010880:Piperidines; D018009:Receptors, Glycine; D016194:Receptors, N-Methyl-D-Aspartate; C109643:Ro 25-6981; D007736:Kynurenic Acid; C066192:5,7-dichlorokynurenic acid; D008559:Memantine